GlassScriptPhysician profile
James M Brock
NPI 1912036823
$1,824.80
in general payments reported to CMS, 2019-2025
20 companies · $320 in 2025
The $320 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.81 · 2020: $157 · 2021: $282 · 2022: $282 · 2023: $300 · 2024: $389 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $843 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $842.90 |
| Education | $165.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $323.50 | 2019-2025 | |
| Janssen Biotech, INC. | $253.57 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Incyte Corporation | $211.72 | 2021-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $202.94 | 2019-2025 | |
| Genzyme Corporation | $163.68 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $108.24 | 2022-2024 | Sotyktu |
| Almirall LLC | $107.57 | 2021-2025 | Klisyri, Seysara |
| Regeneron Healthcare Solutions, INC. | $84.56 | 2020-2024 | Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $69.81 | 2020-2024 | Arazlo |
| Pfizer INC. | $58.25 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $39.03 | 2021-2022 | |
| Leo Pharma INC. | $37.14 | 2023-2024 | Adbry |
| Blueprint Medicines Corporation | $36.70 | 2022 | |
| Journey Medical Corporation | $32.06 | 2022 | |
| Botanix Sb INC | $21.25 | 2025 | Sofdra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medimetriks Pharmaceuticals, INC. | $18.44 | 2025 | Clindacin Etz |
| Galderma Laboratories, L.P. | $14.40 | 2025 | Nemluvio |
| Allergan, INC. | $14.22 | 2019 | |
| Fresenius Kabi USA, LLC | $14.12 | 2024 | Idacio |
| Sandoz INC. | $13.60 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Brock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.